KALINSKI, CEDRIC,ROSS, GUENTHER,BURDACK, CHRISTOPH,WEBER, LUTZ,KHAZAK, VLADIMIR
申请号：
NZ59107309
公开号：
NZ591073A
申请日:
2009.09.15
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed are substituted 2-pyrrolidone compounds of Formula (I), salts thereof, and methods for their preparation. Specific examples of compounds of Formula (I) include: (cis)-4-[1-(4-Bromo-benzyl)-2-(6-chloro-1H-indol-3-yl)-5-oxo-3-p-tolylsulfanyl-pyrrolidine-3-carbonyl]-piperazine-1-carboxylic acid ethylamide, cis-1-[(4-bromophenyl)methyl]-2-(6-chloro-1H-indol-3-yl)-3-[(4-ethylphenyl)sulfanyl]-N-[3-(morpholin-4-yl)propyl]-5-oxopyrrolidine-3-carboxamide, trans-1-[(4-chlorophenyl)methyl]-2-(6-fluoro-1H-indol-3-yl)-N-[3-(morpholin-4-yl)propyl]-5-oxo-3-(phenylsulfanyl)pyrrolidine-3-carboxamide, and cis-2-(6-chloro-1-methyl-1H-indol-3-yl)-1-[(4-chlorophenyl)methyl]-3-[(4-methylphenyl)sulfanyl]-5-oxo-N-(pyridin-2-ylmethyl)pyrrolidine-3-carboxamide. Compounds according to formula (I) are inhibitors of HDM2 and/or MDM2 and are useful for treating cancer and viral infections.
